All Type of News
The domestic launch of the new epilepsy drug, ‘Fycompa’ came close
The domestic launch of a new epilepsy drug is approaching.
The Ministry of Food and Drug Safety approved commercialization of the Eisai’s anti-epilepsy drug, ‘Fycompa(perampanel)’ on the 10th.
Fycompa were approved ...
Boryung Pharm and Zuellig Pharma held the ‘Signing Ceremony for the Exclusive Sales of Kanarb’ to 13 Southeast Asian countriesBoryung Pharm(President Tae-hong Choi) and Zuellig Pharma held the ‘Signing Ceremony for the Exclusive Sales of Kanarb(complete product)’ to 13 Southeast Asian countries at the ...
|
The Ministry of Health and Welfare is discussing the ‘End of MERS’ with the WHO
The Central MERS Crisis Management Center of the Ministry of Health and Welfare unveiled that it has discussed a matter related to the end of the Middle East Respiratory Syndrome(MERS) crisis with the World Health Org...
Viread aims at KRW 100 billion sales as exceeding KRW 50 billion only in the first half of the year
The Gilead’s chronic hepatitis type B treatment, ‘Viread(generic name: tenofovir)’ is expected to make a sales record worth of KRW 50 billion only in the first half of the year.
According to the Yuhan Corporation’s c...
Will the Parkinson’s disease worth of KRW 20 billion be open to the market?
The patent lawsuit of a Parkinson’s disease treatment recording KRW 20 billion annually has attracted attention of the pharmaceutical industry.
Stalevo(entacapone/carbidopa/levodopa) sold by Novartis is the most pres...
Domestic pharmaceutical companies have broken the Sevikar patent, giving generics positive signs
Domestic pharmaceutical companies have succeeded in breaking the Sevikar patent.
According to the Intellectual Property Tribunal, 3 pharmaceutical companies, such as Korea United Pharm, JW Pharmaceutical and JRP, hav...
Abbvie won the patent lawsuit for its HIV treatment against the Ministry of Food and Drug Safety
Abbvie Korea has won the nullity lawsuit of refusal disposition to register the HIV treatment ‘Kaletra Tab’ in the patent roll against the Ministry of Food and Drug Safety.
The 14th Division(Judge Hyeng-jeon Cha) of ...
The Olmesartan and amlodipine complex added adverse events, such as cholelithiasis
Cholelithiasis and dizziness were included in adverse events of the complex of Olmesartan and amlodipine.
On the 8th, the Ministry of Food and Drug Safety unveiled the revision instruction (bill) of approvals for the...
Domestic pharmaceutical companies became troubleshooters in the osteoporosis market
Domestic pharmaceutical companies became troubleshooters in in the depressed osteoporosis market.
Handok unveiled that it has established a co-promotion contract of Bonviva and Bonviva Plus with Roche. The domestic m...
Competition of 83 products in the market of the depression treatment, ‘fluoxetine’
It is known that 83 products have been competing over the domestic depression treatment ‘fluoxetine hydrochloride.’
According to the Ministry of Food and Drug Safety, fluctuation is expected in the domestic market as...
